← All trials
NCT05303701
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2023
- Primary completion
- Oct 30, 2025
- Completion date
- Apr 30, 2026
- First posted
- Mar 31, 2022
- Last posted
- Oct 20, 2022
- Enrollment
- 936
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kael-GemVax Co., Ltd.Lead sponsor
- Kael-GemVax Co., Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.